论文部分内容阅读
以欧达胃克162mg/kg或法莫替丁3.6mg/kg经大鼠灌胃对抗胃溃疡(由吲哚美辛诱导的)和应激性溃疡模型均有明显的保护作用。二药对两种溃疡的抑制率分别为69.5％对71.5％和77.7％对42.7％。又以同样方式对抗乙酸诱导的胃溃疡,其抑制率分别为82.6％和59.6％,实验药的保护作用明显优于对照药。体外试验证明,实验药对幽门螺杆菌(Hp)的抑制作用优于对照药丽珠得乐。欧达胃克抑制慢性溃疡的作用可能与促进上皮细胞和肉芽组织生长及抑制Hp有关。
The gastric ulcer (induced by indometacin) and stress ulcer models were significantly protected by orally gavage 162 mg / kg or famotidine 3.6 mg / kg by intragastric administration. The inhibitory rates of the two drugs on the two ulcers were 69.5% versus 71.5% and 77.7% versus 42.7%, respectively. Again in the same way against acetic acid-induced gastric ulcer, the inhibition rates were 82.6% and 59.6% respectively, and the protective effect of the experimental drug was significantly better than that of the control drug. In vitro tests show that the experimental drug inhibition of Helicobacter pylori (Hp) is better than the control drug Livzonde music. The effect of Otarvek on the inhibition of chronic ulcer may be related to the promotion of epithelial and granulation tissue growth and inhibition of Hp.